TR200807066T1 - Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri - Google Patents

Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri

Info

Publication number
TR200807066T1
TR200807066T1 TR2008/07066T TR200807066T TR200807066T1 TR 200807066 T1 TR200807066 T1 TR 200807066T1 TR 2008/07066 T TR2008/07066 T TR 2008/07066T TR 200807066 T TR200807066 T TR 200807066T TR 200807066 T1 TR200807066 T1 TR 200807066T1
Authority
TR
Turkey
Prior art keywords
hydroxylsulfonamide
hno
new derivatives
nitroxyl donors
physiologically useful
Prior art date
Application number
TR2008/07066T
Other languages
English (en)
Inventor
P. Toscano John
Arthur Brookfield Frederick
Jacob Kalish Vincent
Martin Courtney Stephen
Marie Frost Lisa
D. Cohen Andrew
Original Assignee
Johns Hopkins University School Of Medicine
Cardioxyl Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284031&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200807066(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University School Of Medicine, Cardioxyl Pharmaceuticals, Inc filed Critical Johns Hopkins University School Of Medicine
Publication of TR200807066T1 publication Critical patent/TR200807066T1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Buluş, fizyolojik koşullar altında, kalp yetmezliği ve iskemi/repertuzyon yaralanmaları da dahil olmak üzere, nitroksil (HNO) veren ve nitroksil terapisine cevap veren koşullar veya hastalıkların başlamasını ve/veya gelişmesinin önlenmesinde ve/veya tedavi edilmesinde faydalı olan N-hidroksisülfonamid türevleri ile ilgilidir. Yepyeni N-hidroksisülfonamid türevleri, fizyolojik koşullar altında kontrollü bir hızda HNO serbestlerler ve HNO serbestlenme hızı, N-hidroksisülfonamid türevleri üzerindeki ödevli grupların farklılık gösteren lokasyonu ve tabiatı yoluyla modüle edilir.
TR2008/07066T 2006-03-17 2007-03-16 Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri TR200807066T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78355606P 2006-03-17 2006-03-17

Publications (1)

Publication Number Publication Date
TR200807066T1 true TR200807066T1 (tr) 2009-11-23

Family

ID=38284031

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/07066T TR200807066T1 (tr) 2006-03-17 2007-03-16 Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri

Country Status (25)

Country Link
US (11) US8030356B2 (tr)
EP (8) EP3124471B1 (tr)
JP (4) JP5548869B2 (tr)
KR (7) KR101595781B1 (tr)
CN (4) CN101472576B (tr)
AU (4) AU2007227457B2 (tr)
BR (1) BRPI0708804B8 (tr)
CA (1) CA2645988C (tr)
CY (3) CY1115314T1 (tr)
DK (2) DK2586435T3 (tr)
ES (4) ES2576292T7 (tr)
HK (2) HK1174531A1 (tr)
HU (2) HUE030920T2 (tr)
IL (3) IL193839A (tr)
LT (1) LT2586435T (tr)
MX (3) MX342895B (tr)
NO (2) NO342523B1 (tr)
NZ (4) NZ595770A (tr)
PL (3) PL2489350T3 (tr)
PT (3) PT2489350E (tr)
RU (2) RU2616292C2 (tr)
SG (2) SG170737A1 (tr)
SI (3) SI2586435T1 (tr)
TR (1) TR200807066T1 (tr)
WO (1) WO2007109175A1 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002444A1 (en) * 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
TR200807066T1 (tr) 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
SG10201602375PA (en) * 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
CN102076342B (zh) 2008-05-07 2015-06-10 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CA2782248A1 (en) * 2009-12-07 2011-06-16 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CN102753520B (zh) * 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
SG11201401587QA (en) * 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
EP3567031A1 (en) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
EP2764868A1 (en) 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
WO2015109210A1 (en) * 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2016210392A1 (en) * 2015-06-26 2016-12-29 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof
CN108473439B (zh) * 2015-10-19 2022-03-15 卡尔迪奥克斯尔制药公司 作为硝酰基供体的吡唑啉酮衍生物
CN108368038A (zh) * 2015-10-19 2018-08-03 卡尔迪奥克斯尔制药公司 作为硝酰基供体的n-羟基磺酰胺衍生物
WO2017169894A1 (ja) 2016-03-31 2017-10-05 住友化学株式会社 複素環化合物
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
MX2019008000A (es) 2017-01-03 2019-11-05 Cardioxyl Pharmaceuticals Inc Metodo de administracion de compuestos donadores de nitroxilo.
CN114195731A (zh) * 2021-11-24 2022-03-18 海南大学 一种氢化亚硝酰供体化合物及其制备方法
CN114230495B (zh) * 2021-11-24 2023-01-06 海南大学 一种氢化亚硝酰供体及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US3751255A (en) * 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) * 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0446169A (ja) * 1990-06-14 1992-02-17 Mitsubishi Petrochem Co Ltd 新規なベンゾフラン誘導体及びそれを含有する除草剤
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) * 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
DE69301894T2 (de) 1992-10-28 1996-11-07 Shionogi & Co Benzylidenderivate
JP2728357B2 (ja) * 1992-10-28 1998-03-18 塩野義製薬株式会社 ベンジリデン誘導体
JPH09165365A (ja) * 1995-09-27 1997-06-24 Ono Pharmaceut Co Ltd スルホンアミド誘導体
JPH10142729A (ja) * 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
CN1127492C (zh) * 1997-10-24 2003-11-12 盐野义制药株式会社 抗风湿剂
AU9645798A (en) * 1997-10-24 1999-05-17 Shionogi & Co., Ltd. Antiulcerative
DE19881732D2 (de) * 1997-11-12 2000-08-24 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
LT4727B (lt) 1998-12-29 2000-11-27 Jonas Šarlauskas 5-pakeisti sulfamoilbenzimidazol-2-ilkarbamino rūgščių metilo esteriai, turintys antihelmintinį aktyvumą
WO2000042002A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
DK1218341T3 (da) * 1999-09-01 2005-12-12 Sanofi Aventis Deutschland Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20040121399A1 (en) 2002-12-20 2004-06-24 International Business Machines Corporation Substrate bound linker molecules for the construction of biomolecule microarrays
BRPI0412902A (pt) 2003-08-12 2006-09-26 3M Innovative Properties Co compostos contendo imidazo substituìdo por oxima
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) * 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) * 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
TR200807066T1 (tr) * 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
SG10201602375PA (en) 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
EP3567031A1 (en) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index

Also Published As

Publication number Publication date
US20210053915A1 (en) 2021-02-25
PT2586435T (pt) 2016-12-27
KR20160128447A (ko) 2016-11-07
EP3693363A1 (en) 2020-08-12
JP2017057190A (ja) 2017-03-23
EP2586435A1 (en) 2013-05-01
CN103435524B (zh) 2016-02-10
US10179765B2 (en) 2019-01-15
EP2586435B1 (en) 2016-09-14
KR101878816B1 (ko) 2018-07-16
CN104672115A (zh) 2015-06-03
JP2013144686A (ja) 2013-07-25
CN103435524A (zh) 2013-12-11
USRE45314E1 (en) 2014-12-30
MX368352B (es) 2019-09-30
NO342523B1 (no) 2018-06-04
ES2811258T3 (es) 2021-03-11
CY1115314T1 (el) 2017-01-04
SI2586435T1 (sl) 2016-12-30
CY1117844T1 (el) 2017-05-17
US20170305847A1 (en) 2017-10-26
CN104672115B (zh) 2018-11-23
US20160002156A1 (en) 2016-01-07
SI2489350T1 (sl) 2014-05-30
PT2489350E (pt) 2014-03-10
NZ700984A (en) 2016-05-27
ES2576292T3 (es) 2016-07-06
AU2007227457A1 (en) 2007-09-27
AU2013201667A1 (en) 2013-04-11
DK2586435T3 (en) 2017-01-09
SI2586434T1 (sl) 2016-09-30
CN109438298A (zh) 2019-03-08
AU2016201037B2 (en) 2017-09-14
NZ595770A (en) 2013-04-26
JP6060139B2 (ja) 2017-01-11
BRPI0708804B8 (pt) 2021-05-25
EP2586434B1 (en) 2016-04-27
US9221780B2 (en) 2015-12-29
KR102144926B1 (ko) 2020-08-14
EP3124471A1 (en) 2017-02-01
KR20150091427A (ko) 2015-08-10
MX342895B (es) 2016-10-18
JP2009530303A (ja) 2009-08-27
EP2489350B1 (en) 2013-12-04
EP3124471B1 (en) 2020-06-03
EP2596785A1 (en) 2013-05-29
US9487498B2 (en) 2016-11-08
US20170022154A1 (en) 2017-01-26
WO2007109175A1 (en) 2007-09-27
AU2017221796A1 (en) 2017-09-21
US9969684B2 (en) 2018-05-15
CN101472576A (zh) 2009-07-01
KR20090058476A (ko) 2009-06-09
IL193839A (en) 2015-04-30
CA2645988C (en) 2017-01-10
CY1118237T1 (el) 2017-06-28
KR101473718B1 (ko) 2014-12-17
US10829445B2 (en) 2020-11-10
NZ570971A (en) 2011-11-25
JP2015096525A (ja) 2015-05-21
PL2489350T3 (pl) 2014-08-29
ES2600518T3 (es) 2017-02-09
NO20084355L (no) 2008-12-11
KR20140041941A (ko) 2014-04-04
PT2586434T (pt) 2016-08-05
AU2017221796B2 (en) 2019-10-03
HK1179509A1 (zh) 2013-10-04
NO20180624A1 (no) 2008-12-11
BRPI0708804A2 (pt) 2011-06-14
KR20140147155A (ko) 2014-12-29
US10487049B2 (en) 2019-11-26
PL2586434T3 (pl) 2016-10-31
IL238271A (en) 2017-05-29
US9725410B2 (en) 2017-08-08
EP2489350A1 (en) 2012-08-22
LT2586435T (lt) 2016-12-12
RU2448087C2 (ru) 2012-04-20
RU2011152369A (ru) 2013-06-27
KR101595781B1 (ko) 2016-02-19
JP5764590B2 (ja) 2015-08-19
ES2576292T7 (es) 2022-08-24
AU2016201037A1 (en) 2016-03-10
SG170737A1 (en) 2011-05-30
US20110306614A1 (en) 2011-12-15
ES2448807T3 (es) 2014-03-17
IL217739A0 (en) 2012-03-29
BRPI0708804B1 (pt) 2019-12-17
US20140336396A1 (en) 2014-11-13
IL217739A (en) 2016-09-29
EP2586433A1 (en) 2013-05-01
PL2586435T3 (pl) 2017-06-30
US8030356B2 (en) 2011-10-04
US20070299107A1 (en) 2007-12-27
RU2008141151A (ru) 2010-04-27
EP2586434B3 (en) 2022-04-06
EP1998761A1 (en) 2008-12-10
JP5548869B2 (ja) 2014-07-16
KR20180082639A (ko) 2018-07-18
US20180244610A1 (en) 2018-08-30
US11306056B2 (en) 2022-04-19
US20190144380A1 (en) 2019-05-16
NZ609381A (en) 2014-10-31
CN101472576B (zh) 2013-04-17
AU2007227457B2 (en) 2013-03-28
RU2616292C2 (ru) 2017-04-14
SG10201503828QA (en) 2016-10-28
HUE029309T2 (en) 2017-02-28
CA2645988A1 (en) 2007-09-27
EP2586434A1 (en) 2013-05-01
US20200087253A1 (en) 2020-03-19
HK1174531A1 (en) 2013-06-14
NO343986B1 (no) 2019-08-05
KR102011703B1 (ko) 2019-08-19
KR20190096457A (ko) 2019-08-19
HUE030920T2 (en) 2017-06-28
MX2008011643A (es) 2009-02-10
CN109438298B (zh) 2021-10-08
DK2489350T3 (en) 2014-03-03

Similar Documents

Publication Publication Date Title
TR200807066T1 (tr) Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
MX2010003232A (es) Derivados de n-hidroxisulfonamida como nuevos donadores de nitroxilo fisiologicamente utiles.
UY31472A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
EA201000098A1 (ru) Производные хиназолинамида
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
BRPI0501456A (pt) Membros de segurança e artigos para roupas ìntimas
UY31616A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
CU23743B7 (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas
EA201201648A1 (ru) Стимуляторы sgc
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201000515A1 (ru) Активаторы глюкокиназы
UY31765A (es) Dihidropirazolonas sustituidas y su uso
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
CR11866A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
CO6470792A2 (es) Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
ATE481395T1 (de) Cyclohexylderivate